Replimune Group Beheer

Beheer criteriumcontroles 2/4

De CEO Replimune Group is Sush Patel, benoemd in Apr2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.074% van de aandelen van het bedrijf, ter waarde € 685.28K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 6.4 jaar.

Belangrijke informatie

Sush Patel

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	6.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Sush Patel's beloning veranderd ten opzichte van Replimune Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$213m
Jun 30 2024	n/a	n/a	-US$220m
Mar 31 2024	n/a	n/a	-US$216m
Dec 31 2023	n/a	n/a	-US$210m
Sep 30 2023	n/a	n/a	-US$199m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	US$3m	US$447k	-US$174m
Dec 31 2022	n/a	n/a	-US$157m
Sep 30 2022	n/a	n/a	-US$147m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	US$7m	US$394k	-US$118m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Sush redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de German markt.

Compensatie versus inkomsten: De vergoeding van Sush is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sush Patel (53 yo)

less than a year

Tenure

US$2,595,003

Compensatie

Dr. Sushil Patel, also known as Sush,Ph D, is CEO & Director of Replimune Group, Inc. from April 1, 2024. Dr. Patel served as the Chief Commercial Officer at Replimune Group, Inc. since May 3, 2021 and ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Philip Astley-Sparke	Executive Chairman	9.8yrs	US$6.02m	1.86% € 17.3m
Emily Hill	Chief Financial Officer	1.2yrs	US$3.61m	0.017% € 161.8k
Konstantinos Xynos	Chief Medical Officer	1.9yrs	US$2.45m	0.054% € 503.2k
Sushil Patel	CEO & Director	less than a year	US$2.60m	0.074% € 685.3k
Robert Coffin	Founder	no data	US$5.72m	2.57% € 23.9m
Andrew Schwendenman	Chief Accounting Officer & Treasurer	1.5yrs	geen gegevens	0.010% € 95.5k
Christopher Sarchi	Chief Commercial Officer	1.9yrs	geen gegevens	0.030% € 278.2k
Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	less than a year	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 7R8 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Philip Astley-Sparke	Executive Chairman	9.8yrs	US$6.02m	1.86% € 17.3m
Sushil Patel	CEO & Director	less than a year	US$2.60m	0.074% € 685.3k
Robert Coffin	Founder	9.8yrs	US$5.72m	2.57% € 23.9m
Joseph Slattery	Independent Director	7.1yrs	US$362.60k	0.0097% € 90.7k
Hyam Levitsky	Independent Non-Executive Director	6.5yrs	US$355.10k	0% € 0
Paolo Pucci	Independent Director	4.6yrs	US$360.10k	0% € 0
Madhavan Balachandran	Director	less than a year	geen gegevens	geen gegevens
Kapil Dhingra	Independent Director	7.3yrs	US$357.60k	0% € 0
Christy Oliger	Independent Director	2.9yrs	US$352.60k	0% € 0
Dieter Weinand	Lead Independent Director	6.4yrs	US$516.81k	0% € 0
Veleka Peeples-Dyer	Independent Director	1.4yrs	US$667.97k	0% € 0

6.4yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 7R8 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.4 jaar).

Replimune Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Recent updates

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Now 22% undervalued after recent price drop

Chief Medical Officer Andrea Pirzkall has left the company

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

New 90-day low: €30.40

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

New 90-day high: €41.20

Replimune Group Inc. Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference

New 90-day high: €36.20

Replimune Group, Inc. Appoints Tanya Lewis to its Board of Directors, Effective November 2, 2020

Replimune Group, Inc. Announces Initial Clinical Data of Rp2 and Updated Clinical Data of RP1

New 90-day high - €21.40

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd